IntelGenx Reports Fourth Quarter and Full-Year 2018 Financial Results
March 22, 2019 16:05 ET
|
IntelGenx Technologies Corp.
SAINT LAURENT, Quebec, March 22, 2019 (GLOBE NEWSWIRE) -- IntelGenx Technologies Corp. (TSX-V:IGX)(OTCQX:IGXT) (the "Company" or "IntelGenx") today reported financial results for the fourth quarter...
CORRECTION - IntelGenx to Report Fourth Quarter and Full-Year 2018 Financial Results on March 22, 2019 – Conference Call to Follow on March 25, 2019
March 18, 2019 17:35 ET
|
IntelGenx Technologies Corp.
SAINT LAURENT, Quebec, March 18, 2019 (GLOBE NEWSWIRE) -- In a release issued under a similar headline earlier today by IntelGenx Technologies Corp. (TSX VENTURE:IGX)(OTCQX:IGXT), please note that...
IntelGenx to Report Fourth Quarter and Full-Year 2018 Financial Results on March 25, 2019 – Conference Call to Follow
March 18, 2019 16:00 ET
|
IntelGenx Technologies Corp.
SAINT LAURENT, Quebec, March 18, 2019 (GLOBE NEWSWIRE) -- IntelGenx Technologies Corp. (TSX VENTURE:IGX)(OTCQX:IGXT) today announced that it will release its fourth quarter and full year 2018...
IntelGenx Announces Montreal’s Douglas Mental Health University Institute as Ninth Montelukast VersaFilm™ Phase 2a Clinical Trial Site
February 14, 2019 08:00 ET
|
IntelGenx Technologies Corp.
SAINT LAURENT, Quebec, Feb. 14, 2019 (GLOBE NEWSWIRE) -- IntelGenx Corp. (TSX-V:IGX) (OTCQX:IGXT) (“IntelGenx”), a leading oral drug delivery company, today announced that, subject to final research...
IntelGenx Granted Japanese Patent for RIZAPORT® VersaFilm™
February 11, 2019 08:00 ET
|
IntelGenx Technologies Corp.
SAINT LAURENT, Quebec, Feb. 11, 2019 (GLOBE NEWSWIRE) -- IntelGenx Corp. (TSX-V:IGX) (OTCQX:IGXT) (“IntelGenx”), a leading oral drug delivery company, today announced that it has received a Decision...
IntelGenx Strengthens Senior Management Team
February 07, 2019 16:00 ET
|
IntelGenx Technologies Corp.
SAINT-LAURENT, Québec, Feb. 07, 2019 (GLOBE NEWSWIRE) -- IntelGenx Technologies Corp. (TSXV: IGX) (OTCQX: IGXT), today announced that it has strengthened its management team with the...
IntelGenx Facility Undergoes U.S. FDA Pre-Approval Inspection Related to RIZAPORT® NDA
January 30, 2019 08:00 ET
|
IntelGenx Technologies Corp.
SAINT LAURENT, Quebec, Jan. 30, 2019 (GLOBE NEWSWIRE) -- IntelGenx Corp. (TSX-V:IGX) (OTCQX:IGXT) (“IntelGenx”), a leading oral drug delivery company, today announced that the U.S. Food and Drug...
IntelGenx Provides Update on Phase 2a Montelukast VersaFilm™ Clinical Trial
January 23, 2019 08:00 ET
|
IntelGenx Technologies Corp.
Eight Alzheimer’s Disease Patients Randomized to Date with Two Additional Sites Expected SAINT LAURENT, Quebec, Jan. 23, 2019 (GLOBE NEWSWIRE) -- IntelGenx Corp. (TSX-V:IGX) (OTCQX:IGXT)...
IntelGenx Provides Update on Cannabis-Infused VersaFilm™ Program Following Recently Proposed Amendments to the Cannabis Act
January 14, 2019 08:00 ET
|
IntelGenx Technologies Corp.
Working with partner Tilray®, IntelGenx aims to launch oral film products in late-2019 SAINT LAURENT, Quebec, Jan. 14, 2019 (GLOBE NEWSWIRE) -- IntelGenx Corp. (TSX-V:IGX) (OTCQX:IGXT)...
IntelGenx Partners with Gensco® Pharma to Market RIZAPORT® in the United States
December 12, 2018 08:00 ET
|
IntelGenx Technologies Corp.
SAINT LAURENT, Quebec, Dec. 12, 2018 (GLOBE NEWSWIRE) -- IntelGenx Corp. (TSX-V: IGX) (OTCQX: IGXT) (“IntelGenx”), a leading oral drug delivery company, today announced the execution of a definitive...